PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors

NCT01158300 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

NETWORK

Sponsor class

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG: VEGF inhibitor PTC299

Sponsor

Pediatric Brain Tumor Consortium

Collaborators

[object Object]
[object Object]